News | September 02, 2008

New European Guidelines Issued for Management of Acute Pulmonary Embolism

September 2, 2008 – The European Society of Cardiology (ESC) released new guidelines for how doctors should handle an acute pulmonary embolism (PE), during its 2008 Congress in Munich, Germany today.

The first edition of the ESC Clinical Practice Guidelines on PE was published in 2000. The 2008 update focuses on currently available and validated methods of diagnosis, prognostic evaluation, therapy of PE, and management in specific situations such as pregnancy.

In contrast to previous guidelines, the ESC decided to grade the body of evidence supporting both treatment and diagnostic procedures, because the latter are of particular importance in the management of PE.

For diagnostic tests, the ESC said the most robust data comes from large-scale accuracy or outcome studies. Accuracy studies are designed to establish the value of a diagnostic test (sensitivity and specificity) by comparing test results to a so-called gold standard. Outcome studies evaluate patient outcomes when a given diagnostic test or strategy is used for clinical decision-making. Apart from individual diagnostic tests, the present guidelines review and propose specific diagnostic algorithms, including combinations of tests that permit the confirmation or exclusion of PE in clinical practice using a step-by-step approach. A further section of the guidelines is devoted to prognostic assessment of PE by reviewing and grading the clinical, ultrasound and laboratory findings which allow doctors to estimate the death and complication risk during the early, in-hospital phase of the disease. This assessment and the classification of PE into high-risk, low-risk and intermediate-risk is particularly useful for guiding treatment strategies, which are reviewed in the next section of the guideline.

In high-risk PE, immediate use of thrombolytic drugs (clot busters) or the surgical removal or catheter suction of the clots from the lung vessels is mandatory in order to save the patient’s life. In low-risk PE, however, treatment is less aggressive and focuses on the prevention of future PE episodes. This goal is achieved by the use of so-called anticoagulants (blood thinners), including daily injections of low molecular weight heparin for the first few days, followed by warfarin tablets.

The guideline recommends the use of blood thinners (secondary prevention) for variable periods of time after an episode of PE, depending on the patient’s risk of recurrence. In contrast to these two risk categories, treatment remains controversial in patients with intermediate-risk PE, that is patients who present with normal blood pressure, but with ultrasound and laboratory findings that indicate beginning heart failure.

A large European trial is currently underway to determine whether these patients need clot busters (like the high-risk category) or can be managed with blood thinners alone (like the low-risk category). The trial, entitled Pulmonary Embolism International Thrombolysis Study (PEITHO), is a European investigator-initiated and investigator-sponsored study that is also supported by funds from the French and German governments.

The study began in early 2008 and has already recruited patients in six countries: France, Italy, Germany, Poland, Switzerland, Slovenia. A total of 64 patients have been enrolled so far. Another six countries will be initiated soon. The study plans to randomize as many as 1,000 patients until the end of 2010. It will thus be the largest thrombolysis trial in PE ever performed.

Clots originating in the leg veins may become detached and obstruct the lung vessels. This obstruction may lead to a rise of pressure in the pulmonary circulation and possibly to life-threatening heart failure. PE is a difficult diagnosis that may be missed because of nonspecific complaints. On the other hand, early diagnosis is fundamental since immediate treatment is highly effective. Depending on how critical the patient’s condition is on admission, initial therapy is primarily aimed either at life-saving restoration of blood flow through the occluded pulmonary arteries or at prevention of potentially deadly recurrences (new episodes) of PE.

Fo more information:

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init